Page 2451 - Williams Hematology ( PDFDrive )

2422 Index Index 2423

Deep vein thrombosis (DVT) (Cont.): markers, 1080t for Burkitt lymphoma, 1676
etiology and pathogenesis, 2268 progenitors, 310 for chronic lymphocytic leukemia, 1537
objective testing for, 2269–2270, for vaccine delivery, 422 for diffuse large B-cell lymphoma, 1629t
2272–2273 Dendritic cell sarcomas, 1110 for familial hemophagocytic
therapy. See Venous thrombosis/ Denileukin diftitox lymphohistiocytosis, 1228
thromboembolism, therapy adverse effects, 1687 for follicular lymphoma, 1645t
Defensins, 107, 1009–1010, 1011, 1012t, 1013 for mature T-cell lymphomas, 1695 for hemophagocytic lymphohistiocytosis,
Deferasirox, for iron chelation therapy, 644, mechanism of action, 346 1115
752, 776, 1358 for mycosis fungoides, 1687 for Hodgkin lymphoma, 1616
Deferiprone, for iron chelation therapy, 644, for subcutaneous panniculitis-like T-cell for immune thrombocytopenia, 2004
752, 776 lymphoma, 1702 for myeloma, 1750–1751, 1753t
Deferoxamine, for iron chelation therapy, Denosumab, for myeloma, 1737 for Waldenström macroglobulinemia,
751–752, 1358 Dense granules, platelet, 1843 1794–1795
Deferoxamine mesylate, 5 Dense tubular system (DTS), 1836 Dexrazoxane, cardioprotective effects, 1396,
Defibrotide, 368 Dental bleeding/extractions 1520
Deformin, 818 antibiotic prophylaxis, 869 Dextran, 2079
Degranulation, 948 antifibrinolytic therapy for, 2317t DGKE/DGKE, 2260, 2261
Degranulation abnormalities fibrin glue for, 2157 DGKH, 233t
Chédiak-Higashi syndrome. gingival bleeding, 5, 8, 1987 DHAP regimen
See Chédiak-Higashi syndrome in hemophilia, 2120 for diffuse large B-cell lymphoma, 1629t,
specific granule deficiency, 1019t, in hemostatic disorders, 1987, 1988 1631
1020–1021 2′-Deoxycoformycin. See Pentostatin for Hodgkin lymphoma, 1616
Dehydrated stomatocytosis. See Hereditary (deoxycoformycin) for peripheral T-cell lymphoma, 1696
xerocytosis Deoxyhemoglobin, 761, 761f DHFR (dihydrofolate reductase), 318, 584
Delayed hemolytic transfusion reaction Deoxynucleotide synthesis, 587f DHFR (dihydrofolate reductase) deficiency,
(DHTR), 2372, 2377 Deoxypyridinoline (DPD), 1738 608
Deletions, chromosomal, 175t Deoxyuridine (dU) suppression test, 594, DHTR (delayed hemolytic transfusion
δβ-thalassemias, 726 598, 603 reaction), 2372
0
A
( γδβ) , 733, 733t Depsipeptide, 335, 1403 Diabetes insipidus (DI)
clinical features, 743 Desferrioxamine, 639, 644, 751, 776 in acute myelogenous leukemia, 1384
+
(δβ) , 733–734, 735f, 748 Desirudin, 2030 in Langerhans cell histiocytosis, 1104–
0
(δβ) , 733, 748 Desmopressin (DDAVP) 1105
epidemiology/population genetics, adverse effects, 2175 Diabetes mellitus, hemostasis and, 2203
727–728 for bleeding Diacylglycerol (DAG), 935, 1016, 1849
laboratory features, 750f in chronic myeloproliferative neoplasms, Dialysis, 2083–2084
molecular basis, 733–734, 733t, 734f, 735f 2081 Diamond-Blackfan anemia (inherited pure
nondeletion, 734–735 in fibrinolytic therapy, 2317 red cell anemia), 539–540, 994
Delta ligand, 1824 in inherited platelet disorders, 2061– Diamond-Blackfan syndrome, 2340
δ-storage pool deficiency, 2052–2054 2062 Diapedesis, 1059
δ-thalassemias, 726, 736, 751 postsurgical, 2086 Diaphragmatic hernia, blood loss from, 629
Demargination (pseudoneutrophilia), in uremia, 2084 Diarrhea, history of, 5
999–1000 for combined deficiency of factors V and Diazoxide, maternal ingestion of, effect on
Dematin, 663t VIII, 2140 fetus and newborn, 112, 112t
Demethylating agents, 239, 336. See also for hemophilia A, 2122–2123, 2185 DIC. See Disseminated intravascular
5-Azacytidine; Decitabine release of von Willebrand factor and factor coagulation (DIC)
Dendritic cells (DCs) VIII and, 2166 Dickkopf-1 (DKK1), 1713, 1737, 1738,
antigen uptake and processing in, 308–309 for von Willebrand disease, 2175 1739f
blood, 1092, 1098 contraindication during pregnancy, 121 Diclofenac, 2075
in cellular therapy, 413 Deviation, 1275 Didanosine, 1249
classification, 309–310 Dexamethasone. See also HyperCVAD Diego blood group/antigens, 2331t, 2337,
development, 309, 1151 regimen 2345t
differentiation, 1076f for acute lymphoblastic leukemia, 1515, Dietary restriction, aging and, 131–132
functions, 307–308, 308t 1516, 1517 Diferric transferrin pool, 491
in immunotherapy, 310 adverse effects, 1519t Differential count
in Langerhans cell histiocytosis, 1103 for AL amyloidosis, 1779–1781 in children, 15t
in malignant histiocytosis, 1101 for α-heavy-chain disease, 1808 in newborn, 105, 105t

Kaushansky_index_p2393-2506.indd 2422 9/21/15 3:21 PM